"Ciprofloxacin-induced" bilateral quadriceps tendon rupture: A case report and conclusions of the recent literature

Rifampin-loaded Mesoporous Silica Nanoparticles Improved Physical and Mechanical Properties and Biological Response of Acrylic Bone Cement

Background

Acrylic bone cement, which is used to fix implants in the knee and hip, is prone to contamination with various types of infections. Adding small amounts of different antibiotics to the cement can help prevent and treat infections. Rifampin antibiotic has been added to bone cement to create an appropriate antimicrobial response in the treatment of resistant coagulase-negative staphylococci (CoNS) biofilms, but there are some challenges such as reducing mechanical properties and prolonging the setting time of the cement. Loading the antibiotic in the nanoparticle could eliminate these challenges.

Methods

In this study, rifampin-loaded mesoporous silica nanoparticles (MSNs) were added to bone cement, and the polymerization components, mechanical properties, drug release, antibacterial activity, and cellular response were investigated and compared with commercial pure cement and the cement containing free rifampin.

Results

Loading rifampin into MSN improved compressive strength by 57.52%. Cement containing rifampin loaded into MSN showed remarkable success in antibacterial activity. The growth inhibition zone created by it in the culture medium of Staphylococcus aureus and CoNS was 15.44% and 11.8% greater, respectively, than in the cement containing free rifampin. In other words, according to the results of spectrophotometric analysis of cement samples over 5 weeks, MSNs caused a 33.2 ± 0.21-fold increase in rifampin washout from the cement. Cellular examination of the cement containing rifampin loaded into MSN compared to commercial pure cement showed an acceptable level of cell viability.

Conclusion

Rifampin loading in MSN limited the reduction of cement strength. It also improved the drug release pattern and prevented antibiotic resistance.

Drug Utilization Evaluation Study of Ciprofloxacin Use and Adverse Events Occurrence: Role of Community Pharmacists

Background: Antimicrobial resistance is a global health crisis threatening optimal management of infectious diseases. Ciprofloxacin is a widely used fluoroquinolone in various disease conditions. Resistance against ciprofloxacin is increasing, leading to nonoptimal management of patients. Thus, the aim of this study was to assess ciprofloxacin use in the community setting in terms of appropriate prescribing, dosing, frequency, and duration of use. Methods: A cross-sectional, retrospective study was conducted by community pharmacists in 5 community pharmacies in Egypt from September 2021 to February 2022. Patients prescribed oral ciprofloxacin during the period of the study were included. Data on demographics, indications for ciprofloxacin, dosing regimen, adverse events, and drug interactions were collected. Results: A total of 151 patients' record indicated for ciprofloxacin were included in the study, of whom 44.4% were men and 55.6% were women who were neither pregnant nor lactating. Based on international guidelines, 96.69% ciprofloxacin prescriptions were appropriate; 96.03% contained correct ciprofloxacin dosing whereas 3.97% were overdose. A total of 90. 73% had correct frequency of administration and 96.03% records had correct durations. Only 1.99% of patients were ≤18 years of age, which is an absolute contraindication. Interacting drugs with ciprofloxacin were 28.5% with acetaminophen, 31.1% with ibuprofen, 16.6% with antacids, 21.2% with chlorpheniramine, and 7.9% with prednisolone. Adverse events included 1.32% hypoglycemia, 0.66% hyperglycemia, 3.97% tendinitis, and 2.65% QTc (heart rate-corrected QT interval) prolongation. Conclusion and relevance: Ciprofloxacin use in community pharmacies is appropriate according to international guidelines. Ongoing drug utilization evaluation is necessary to ensure rational drug use, which in turn can decrease resistance rates.

Ciprofloxacin-Loaded Titanium Nanotubes Coated with Chitosan: A Promising Formulation with Sustained Release and Enhanced Antibacterial Properties

Due to their high entrapment efficiency, anodized titanium nanotubes (TiO2-NTs) are considered effective reservoirs for loading/releasing strong antibiotics whose systemic administration is associated with diverse and severe side-effects. In this study, TiO2-NTs were synthesized by anodic oxidation of titanium foils, and the effects of electrolyte percentage and viscosity on their dimensions were evaluated. It was found that as the water content increased from 15 to 30%, the wall thickness, length, and inner diameter of the NTs increase from 5.9 to 15.8 nm, 1.56 to 3.21 µm, and 59 to 84 nm, respectively. Ciprofloxacin, a highly potent antibiotic, was loaded into TiO2-NTs with a high encapsulation efficiency of 93%, followed by coating with different chitosan layers to achieve a sustained release profile. The prepared formulations were characterized by various techniques, such as scanning electron microscopy, differential scanning calorimetry, and contact measurement. In vitro release studies showed that the higher the chitosan layer count, the more sustained the release. Evaluation of antimicrobial activity of the formulation against two endodontic species from Peptostreptococcus and Fusobacterium revealed minimum inhibitory concentrations (MICs) of 1 µg/mL for the former and the latter. To summarize, this study demonstrated that TiO2-NTs are promising reservoirs for drug loading, and that the chitosan coating provides not only a sustained release profile, but also a synergistic antibacterial effect.

Secretory System Components as Potential Prophylactic Targets for Bacterial Pathogens

Bacterial secretory systems are essential for virulence in human pathogens. The systems have become a target of alternative antibacterial strategies based on small molecules and antibodies. Strategies to use components of the systems to design prophylactics have been less publicized despite vaccines being the preferred solution to dealing with bacterial infections. In the current review, strategies to design vaccines against selected pathogens are presented and connected to the biology of the system. The examples are given for Y. pestis, S. enterica, B. anthracis, S. flexneri, and other human pathogens, and discussed in terms of effectiveness and long-term protection.